X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (7248) 7248
Book Review (1691) 1691
Publication (366) 366
Book Chapter (93) 93
Conference Proceeding (56) 56
Magazine Article (32) 32
Book / eBook (14) 14
Dissertation (8) 8
Newspaper Article (2) 2
Reference (2) 2
Data Set (1) 1
Newsletter (1) 1
Paper (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (5234) 5234
humans (4776) 4776
vitamin k - antagonists & inhibitors (2552) 2552
warfarin (2250) 2250
male (2132) 2132
female (2057) 2057
anticoagulants (1816) 1816
anticoagulants - therapeutic use (1730) 1730
aged (1545) 1545
vitamin k (1415) 1415
anticoagulants - adverse effects (1373) 1373
middle aged (1291) 1291
atrial fibrillation (1287) 1287
anticoagulants - administration & dosage (1228) 1228
hematology (1110) 1110
risk factors (1046) 1046
administration, oral (1026) 1026
peripheral vascular disease (921) 921
stroke (910) 910
animals (908) 908
dabigatran (844) 844
vitamin k antagonists (809) 809
anticoagulation (797) 797
hemorrhage - chemically induced (786) 786
cardiac & cardiovascular systems (783) 783
international normalized ratio (776) 776
atrial fibrillation - drug therapy (769) 769
adult (766) 766
aged, 80 and over (765) 765
thromboembolism (757) 757
rivaroxaban (719) 719
risk (672) 672
therapy (649) 649
venous thromboembolism (640) 640
vitamin-k antagonists (639) 639
treatment outcome (636) 636
atrial-fibrillation (635) 635
management (629) 629
pharmacology & pharmacy (612) 612
abridged index medicus (576) 576
stroke - prevention & control (573) 573
medicine, general & internal (570) 570
prevention (565) 565
bleeding (553) 553
atrial fibrillation - complications (552) 552
patients (514) 514
thrombosis (487) 487
warfarin - therapeutic use (484) 484
warfarin - adverse effects (479) 479
analysis (468) 468
vitamin k antagonist (459) 459
hemorrhage (454) 454
warfarin - administration & dosage (448) 448
apixaban (447) 447
care and treatment (439) 439
medicine & public health (435) 435
thromboembolism - prevention & control (413) 413
oral anticoagulants (410) 410
retrospective studies (410) 410
cardiac arrhythmia (402) 402
safety (399) 399
stroke prevention (395) 395
rats (394) 394
time factors (393) 393
anticoagulants - pharmacology (390) 390
blood coagulation - drug effects (387) 387
drug therapy (372) 372
oral anticoagulation (367) 367
vitamin-k (356) 356
vitamin k - pharmacology (351) 351
antithrombotic therapy (344) 344
mortality (344) 344
cardiology (340) 340
fibrillation (336) 336
dose-response relationship, drug (332) 332
vitamin k - therapeutic use (332) 332
health aspects (330) 330
antagonists (329) 329
prospective studies (329) 329
research (325) 325
prothrombin (322) 322
vitamins (321) 321
stroke - etiology (316) 316
risk assessment (314) 314
internal medicine (313) 313
thrombin (311) 311
molecular-weight heparin (304) 304
dosage and administration (295) 295
prothrombin complex concentrate (285) 285
aspirin (281) 281
deep-vein thrombosis (278) 278
heparin - therapeutic use (278) 278
heparin (275) 275
venous thromboembolism - drug therapy (275) 275
warfarin - pharmacology (270) 270
fibrinolytic agents - therapeutic use (267) 267
surgery (267) 267
coagulation (263) 263
metaanalysis (263) 263
randomized controlled trials as topic (257) 257
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (6068) 6068
French (606) 606
German (324) 324
Spanish (106) 106
Russian (60) 60
Italian (39) 39
Japanese (37) 37
Danish (24) 24
Portuguese (24) 24
Hungarian (20) 20
Polish (20) 20
Dutch (14) 14
Korean (11) 11
Chinese (6) 6
Romanian (6) 6
Norwegian (5) 5
Swedish (5) 5
Czech (4) 4
Turkish (3) 3
Bulgarian (2) 2
Croatian (2) 2
Slovenian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Circulation, ISSN 0009-7322, 09/2013, Volume 128, Issue 11, pp. 1234 - 1243
BACKGROUND—Patients experiencing major bleeding while taking vitamin K antagonists require rapid vitamin K antagonist reversal. We performed a prospective... 
CARDIAC & CARDIOVASCULAR SYSTEMS | ORAL ANTICOAGULANT REVERSAL | CLINICAL-TRIAL | RECOMBINANT FACTOR-VIII | vitamin K antagonist | prothrombin complex concentrates | PREVIOUSLY UNTREATED PATIENTS | INTRACRANIAL HEMORRHAGE | THERAPY | WARFARIN | TRANSFUSION | HEMOPHILIA-A | anticoagulants | PERIPHERAL VASCULAR DISEASE | plasma | FRESH-FROZEN PLASMA | hemorrhage | Single-Blind Method | Plasma | Prospective Studies | Thromboembolism - chemically induced | Factor IX - therapeutic use | Humans | Middle Aged | Male | Factor IX - adverse effects | Hemorrhage - prevention & control | Vitamin K - antagonists & inhibitors | Thromboembolism - prevention & control | Aged, 80 and over | Adult | Factor X - therapeutic use | Female | Factor X - adverse effects | Factor VII - adverse effects | Factor VII - therapeutic use | Emergencies | Anticoagulants - therapeutic use | Treatment Outcome | Prothrombin - therapeutic use | Anticoagulants - adverse effects | Prothrombin - adverse effects | Hemostatics - adverse effects | International Normalized Ratio | Hemorrhage - drug therapy | Blood Coagulation Factors - adverse effects | Anticoagulants - pharmacology | Blood Coagulation Factors - therapeutic use | Aged | Hemorrhage - chemically induced | Hemostatics - therapeutic use | Drug Combinations | Antidotes - therapeutic use | Antagonists (Biochemistry) | Usage | Care and treatment | Blood coagulation factors | Health aspects | Hemorrhage | Index Medicus | Abridged Index Medicus
Journal Article
Circulation, ISSN 0009-7322, 2015, Volume 132, Issue 13, pp. 1252 - 1260
Background-The safety and effectiveness of non-vitamin K antagonist (VKA) oral anticoagulants, dabigatran or rivaroxaban, were compared with VKA in... 
atrial fibrillation | databases, factual | Databases | Factual | anticoagulants | comparative effectiveness research | France | stroke | hemorrhage | pharmacoepidemiology | CARDIAC & CARDIOVASCULAR SYSTEMS | ANTICOAGULATION CONTROL | METAANALYSIS | QUALITY | EFFICACY | SAFETY | PREVENTION | THERAPY | WARFARIN | ORAL ANTICOAGULANTS | PERIPHERAL VASCULAR DISEASE | Dabigatran - adverse effects | Follow-Up Studies | Humans | Middle Aged | Hospitalization - statistics & numerical data | Warfarin - adverse effects | Risk | Dabigatran - therapeutic use | Thrombophilia - etiology | Warfarin - therapeutic use | Young Adult | Vitamin K - antagonists & inhibitors | Rivaroxaban - adverse effects | Thromboembolism - prevention & control | Adult | Rivaroxaban - therapeutic use | Thrombophilia - drug therapy | Databases, Factual | Antithrombins - therapeutic use | Atrial Fibrillation - complications | Anticoagulants - therapeutic use | Thromboembolism - etiology | Anticoagulants - adverse effects | Arterial Occlusive Diseases - etiology | Factor Xa Inhibitors - therapeutic use | Antithrombins - adverse effects | Factor Xa Inhibitors - adverse effects | Adolescent | Aged | Arterial Occlusive Diseases - prevention & control | Hemorrhage - chemically induced | Antagonists (Biochemistry) | Complications and side effects | Rivaroxaban | Atrial fibrillation | Dosage and administration | Thromboembolism | Drug therapy | Comparative analysis | Hemorrhage | Risk factors | Index Medicus | Abridged Index Medicus | 184 | Original | 185
Journal Article
American Heart Journal, ISSN 0002-8703, 2017, Volume 190, pp. 12 - 18
Background Oral anticoagulation prevents ischemic strokes in patients with atrial fibrillation. Early detection of atrial fibrillation and subsequent... 
Cardiovascular | FIBRILLATION | CARDIAC & CARDIOVASCULAR SYSTEMS | STROKE PREVENTION | WARFARIN | CLINICAL-IMPLICATIONS | AMERICAN-COLLEGE | CARDIAC MONITOR | RISK | OPEN-LABEL | TEMPORAL RELATIONSHIP | ISCHEMIC-STROKE | Prospective Studies | Follow-Up Studies | Humans | Male | Thiazoles - administration & dosage | Atrial Fibrillation - physiopathology | Aspirin - administration & dosage | Factor Xa Inhibitors - administration & dosage | Incidence | Time Factors | Female | Stroke - epidemiology | Vitamin K | Heart Rate | Stroke - prevention & control | Pyridines - administration & dosage | Survival Rate - trends | Double-Blind Method | Administration, Oral | Atrial Fibrillation - drug therapy | Risk Factors | Europe - epidemiology | Treatment Outcome | Disease-Free Survival | Stroke - etiology | Atrial Fibrillation - epidemiology | Aged | Fibrinolytic Agents - administration & dosage | Stroke (Disease) | Care and treatment | Anticoagulants (Medicine) | Stroke patients | Atrial fibrillation | Cardiac patients | Implants, Artificial | Prosthesis | Anticoagulants | Therapy | Cardiac arrhythmia | Surgical implants | Aspirin | Stroke | Coagulation | Strokes | Patients | Bleeding | Risk factors | Vitamins | Artifacts | Fibrillation | Ischemia | Defibrillators | Pacemakers | Safety engineering | Electrocardiography | Heart diseases | Index Medicus | Abridged Index Medicus | Trial Design
Journal Article
Journal Article
Journal Article
Thrombosis and Haemostasis, ISSN 0340-6245, 10/2016, Volume 116, Issue 4, pp. 754 - 763
In the RE-LY clinical trial, dabigatran presented a better effectiveness/safety profile when compared to warfarin. However, clinical trials are not very... 
Dabigatran | Vitamin K antagonist | Atrial fibrillation | Real-world | Meta-analysis | POPULATION | SAFETY | RIVAROXABAN | meta-analysis | RISK | MYOCARDIAL ISCHEMIC EVENTS | vitamin K antagonist | INTRACRANIAL HEMORRHAGE | STROKE | real-world | WARFARIN | ORAL ANTICOAGULANTS | dabigatran | PERIPHERAL VASCULAR DISEASE | THROMBOEMBOLISM | HEMATOLOGY
Journal Article
JAMA - Journal of the American Medical Association, ISSN 0098-7484, 02/2018, Volume 319, Issue 5, pp. 463 - 473
Journal Article